Furthermore, our results may have important clinical implications by prospecting the non-invasive i.v. delivery route of 12A12mAb as effective and safe disease-modifying approach in contrasting the earliest neuropathological and cognitive alterations of subjects which suffer the chronically developing human Alzheimer’s disease and non-Alzheimer’s disease tauopathies characterized by an increased burden of tau truncation. This evidence concerns the gene MAPT and tauopathy.